| Autor: |
Rebecca L, Geary, Nur Azri Bin Haji, Yasin, Frank, Lin, Deborah, Whalley, Ziad, Thotathil, Charles, De Groot |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
The New Zealand medical journal. 134(1529) |
| ISSN: |
1175-8716 |
| Popis: |
Stereotactic ablative radiotherapy (SABR) involves the delivery of high doses of precisely targeted radiation in a shorter time period than conventional radiotherapy. The aim of this study was to compare the outcomes of lung-based SABR in a New Zealand cohort to the global literature.A single-institution retrospective analysis was performed on all patients who received lung-based SABR between May 2015 and September 2019 at Waikato Hospital, New Zealand. The study included both early stage lung cancer and lung oligometastases that measured less than 5cm.102 patients received SABR to 116 lesions. Median follow-up was 19 months. The three-year rate of local control in the primary and metastatic cohorts was 85% and 82%, respectively. This reflects the three-year local control rate of 86% for primary lung cancer in the SPACE trial and the two-year local control rate of 81% for pulmonary oligometastases in a German study. Central primary lung cancer was associated with a higher risk of local recurrence (HR6.4 (1.3-31.5) p=0.02). The three-year progression-free survival rate in patients with early stage lung cancer and oligometastases was 56% and 26%, respectively. Māori patients with primary lung cancer had a significantly worse progression free survival (HR2.4 (1.1-5.1) p=0.03). There were no reported grade three toxicities.The use of lung-based SABR in a typical radiotherapy setting in New Zealand mirrors global outcomes. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
